公开(公告)号：US20230251247A1

公开(公告)日：2023-08-10

申请号：US18104578

申请日：2023-02-01

Applicant: Horizon Therapeutics USA, Inc.

Inventor： Theresa ROSARIO-JANSEN ,  David Erick WRIGHT

IPC: G01N33/53 ,  G01N33/68 ,  A61K47/60 ,  A61P19/02 ,  A61K9/00 ,  A61K38/44

CPC classification number: G01N33/5308 ,  G01N33/6893 ,  A61K47/60 ,  A61P19/02 ,  A61K9/0019 ,  A61K38/44 ,  C12Y107/03003 ,  G01N2800/107 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2333/90694

Abstract: Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions.

公开(公告)号：US20230243852A1

公开(公告)日：2023-08-03

申请号：US18160000

申请日：2023-01-26

Applicant: IDEXX LABORATORIES, INC.

Inventor： Sarah Maier PETERSON ,  Yerramilli V.S.N. MURHTY

IPC: G01N33/68

CPC classification number: G01N33/6893 ,  G01N2333/775 ,  G01N2333/8139 ,  G01N2800/56 ,  G01N2800/347

Abstract: The disclosure provides methods and compositions for detection and differentiation of stable CKD and progressive CKD in mammals.

公开(公告)号：US20230236195A1

公开(公告)日：2023-07-27

申请号：US18100076

申请日：2023-01-23

Applicant: JOINSTAR BIOMEDICAL TECHNOLOGY CO., LTD.

Inventor： Baoqing SUN ,  Nanshan ZHONG ,  Xuyi ZHOU ,  Mingshan XUE ,  Longbin HONG ,  Ming DONG

IPC: G01N33/68

CPC classification number: G01N33/68 ,  G01N2333/4703 ,  G01N2800/56

Abstract: Provided are a method for predicting a risk of deterioration of a pathogenic condition of a patient suffering a coronavirus disease (COVID-19), especially a severe patient suffering a COVID-19 and a kit thereof. The method of the present application may effectively predict the deterioration of the pathogenic condition of the patient suffering a COVID-19, thereby carrying out clinical intervention in advance, to improve prognosis of the patient suffering a COVID-19. The present application finds for the first time that the level of a heparin-binding protein (HBP) can be used as a significant indicator for early predicting relapse of the patient suffering a COVID-19, expression time of an HBP indicator is around 5 days earlier than that of a series of other clinical indicators, and thus the HBP indicator particularly has a clinical value.

公开(公告)号：US20230213536A1

公开(公告)日：2023-07-06

申请号：US18147094

申请日：2022-12-28

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/56 ,  G01N2800/28

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, glial fibrillary acidic protein (GFAP), in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

公开(公告)号：US20230194548A1

公开(公告)日：2023-06-22

申请号：US18110229

申请日：2023-02-15

Applicant: Exagen Inc.

Inventor： Thierry Dervieux ,  Cole Harris

IPC: G01N33/68 ,  G01N33/564

CPC classification number: G01N33/6854 ,  G01N33/564 ,  G01N2800/104 ,  G01N2800/56

Abstract: The present invention provides methods of diagnosing and monitoring systemic lupus erythematosus.

公开(公告)号：US11650214B2

公开(公告)日：2023-05-16

申请号：US17116429

申请日：2020-12-09

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ CÔTE D'AZUR ,  CHU DE NICE

Inventor： Thierry Passeron ,  Florence Joly

IPC: A61K31/422 ,  G01N33/68 ,  G01N33/50 ,  A61K31/506 ,  A61K33/14 ,  C12Q1/6883

CPC classification number: G01N33/6893 ,  A61K31/422 ,  A61K31/506 ,  A61K33/14 ,  C12Q1/6883 ,  G01N33/5008 ,  G01N33/5023 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N2800/207 ,  G01N2800/52 ,  G01N2800/56

Abstract: The present invention relates to the identification of proteins of the WNT signaling pathway as therapeutic targets of pigmentation disorder and as biomarkers of pigmentation status.
The invention in particular relates to products and methods for treating a hypopigmentation disorder.
The invention also relates to products and methods for detecting, diagnosing, staging or monitoring the course of hypopigmentation disorder and is particularly suited for human subjects.

公开(公告)号：US20190249215A1

公开(公告)日：2019-08-15

申请号：US16272251

申请日：2019-02-11

Applicant: Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center

Inventor： Ruchi Malik ,  Edna Cukierman ,  Peter I. Lelkes

IPC: C12Q1/02 ,  C12N5/00 ,  C12N5/09

CPC classification number: C12Q1/025 ,  C12N5/0018 ,  C12N5/0693 ,  C12N2533/90 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/7028

Abstract: The present disclosure provides extracellular matrix (ECM)/gel systems that have a substrate having a gel on a surface thereof, and a cell-derived matrix (CDM) on the surface of the gel, and methods of making ECM/gel systems, and methods of using ECM/gel systems to, for example, screen agents for anti-cancer or anti-fibrotic activity.

公开(公告)号：US20190194305A1

公开(公告)日：2019-06-27

申请号：US16214455

申请日：2018-12-10

Applicant: DIADEM S.R.L.

Inventor： Maurizio MEMO ,  Daniela Uberti

IPC: C07K16/18 ,  C07K16/32 ,  G01N33/68

CPC classification number: C07K16/18 ,  C07K16/32 ,  C07K2317/34 ,  G01N33/6896 ,  G01N2333/4748 ,  G01N2800/2821 ,  G01N2800/56 ,  G01N2800/7042

Abstract: The invention relates to an anti-human p53 antibody suitable for specifically binding a linear epitope which is exposed only in a conformationally altered isoform of the characteristic p53 protein of patients with Alzheimer's disease or prone to develop Alzheimer's disease or cognitive impairment during ageing. Methods and diagnostic and prognostic kits are also described.

公开(公告)号：US20180356429A1

公开(公告)日：2018-12-13

申请号：US15700790

申请日：2017-09-11

Applicant: Genentech, Inc. ,  Hoffmann-La Roche Inc.

Inventor： Alyssa Morimoto ,  Kun Peng ,  Heleen Scheerens ,  Fang Cai ,  Hans Hornauer

IPC: G01N33/68

CPC classification number: G01N33/6869 ,  A61K2039/505 ,  A61K2039/55 ,  C07K16/244 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/76 ,  G01N33/50 ,  G01N33/574 ,  G01N2333/5437 ,  G01N2800/122 ,  G01N2800/52 ,  G01N2800/56

Abstract: Methods of detecting and quantifying IL-13 are provided. Also provided are methods of diagnosing, selecting and identifying patients with Th2-associated diseases (Type 2-associated diseases) for treatment with certain therapeutic agents that are Th2 pathway inhibitors (Type 2 pathway inhibitors).

公开(公告)号：US20180346558A1

公开(公告)日：2018-12-06

申请号：US16058630

申请日：2018-08-08

Applicant: Neurimmune Holding AG

Inventor： Jan GRIMM ,  Fabrice Heitz ,  Feng Chen ,  Ioana Combaluzier

IPC: C07K16/18 ,  C07K7/06 ,  C07K14/47 ,  G01N33/543 ,  G01N33/577 ,  G01N33/68 ,  A61K39/00

CPC classification number: C07K16/18 ,  A61K2039/505 ,  C07K7/06 ,  C07K14/4711 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/54306 ,  G01N33/577 ,  G01N33/6893 ,  G01N2333/47 ,  G01N2333/4709 ,  G01N2800/042 ,  G01N2800/52 ,  G01N2800/56

Abstract: Provided are novel human islet amyloid polypeptide, also known as amylin and IAPP and proIAPP respectively, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for IAPP and/or proIAPP are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for IAPP and/or proIAPP targeted immunotherapy and diagnostics, respectively.